Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
No Thumbnail Available
Authors
Mountzios, Giannis
Weng, Julius K.
Zairi, Eleni
Hsieh, Kristin
Chander, Pratibha
Dunlop, William
Qiao, Yao
Wang, Alice
Januszewski, Adam
Contact
Check for full-text access
Issue Date
2026
Type
Article
Language
Keywords
Alternative Title
Abstract
INTRODUCTION: Many patients with unresectable stage III non-small-lung cancer (NSCLC) may face challenges in receiving consolidation durvalumab following concurrent chemoradiotherapy (cCRT) due to incomplete cCRT or disease progression. The retrospective POSITION study characterized this population. METHODS: Adults with unresectable stage III NSCLC diagnosed between 2010 and 2021 who received cCRT were identified from TEMPUS Oncology (database). Among these patients, we estimated proportions with incomplete cCRT or progression during/within 42 days of cCRT and assessed overall survival (OS). Factors associated with incomplete cCRT or progression during/within 42 days of cCRT were identified via multivariable logistic regression. RESULTS: Of 2076 eligible patients, 23.0% had incomplete cCRT (Group A), 12.7% experienced progression during/within 42 days of cCRT (Group B), and 64.3% completed cCRT without progression (Group C). Median OS (95% CI) was 21.6 (17.2-28.0), 10.1 (7.2-12.5), and 32.4 (29.8-34.6) months for Groups A, B, and C, respectively. Landmark 60-month OS rates were 26.3%, 11.6% and 33.2% for Groups A, B and C, respectively. Higher comorbidity burden (Charlson Comorbidity Index) and Black (vs. White) race were associated with higher likelihood of incomplete cCRT. Stage IIIB/C (vs. IIIA), cerebrovascular, and renal disease were associated with higher likelihood of progression during/within 42 days of cCRT. CONCLUSION: In POSITION, 35.7% of patients had incomplete cCRT or progressed during/within 42 days of cCRT and may have faced challenges receiving consolidation durvalumab; race, disease stage, and comorbidities were associated with incomplete cCRT or progression.
Description
Citation
Publisher
License
Journal
Clinical lung cancer